Gerson Lehrman Group - Intelligently Connecting Institutions and Expertise.

Study Group: Multiple Myeloma Physicians

Council Members in this Study Group: 211

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Contact Gerson Lehrman Group to survey or consult with members of this Study Group

Leading institutions connect with members of this Study Group through GLG

Leading Experts in this Study Group

Robert Boorstein, MD, PhD

Associate Professor, Pathology
NEW YORK UNIVERSITY (INC)
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Robert Boorstein, MD, PhD, is an Associate Professor in the Department of Pathology at New York University School of Medicine, where he directs clinical pathology training. Previously, Dr. Boorstein was the Director of Pathology at Bellevue Hospital and the Medical Director for Pathology and Laboratory...

16 recent news post(s)
Donald Fleming, MD, Division Head of Hematology and Oncology, DAVIS HEALTH SYSTEM INCDonald Fleming, MD

Division Head of Hematology and Oncology
DAVIS HEALTH SYSTEM INC
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Donald Fleming, MD, is the Head of Hematology-Oncology at the Medical Center of Vincennes. Previously, Dr. Fleming was a Tenured Professor in the Division of Hematology-Oncology at University of Louisville. He has published over 25 manuscripts in peer-reviewed journals and remains involved in clinical...

105 recent news post(s)
Eric Jacobsen, MD

Instructor in Medicine
DANA-FARBER CANCER INSTITUTE, INC.
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Eric Jacobsen, MD, is Medical Oncologist and Hematologist in the Hematology/Oncology Department at the Dana-Farber Cancer Institute in Boston, MA. Dr. Jacobsen is a member of the lymphoma and bone marrow transplant divisions at Dana-Farber Cancer Institute and an Instructor in Medicine at HarvardMedical...

Taral Patel, MD, Oncologist, MID-OHIO ONCOLOGY & HEMOTOLOGY INCTaral Patel, MD

Oncologist
MID-OHIO ONCOLOGY & HEMOTOLOGY INC
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Taral Patel, MD, is an Oncologist in private practice with Mid Ohio Oncology-Hematology, Inc. He treats patients with both cancer and blood disorders. Dr. Patel has been a principal investigator for multiple clinical trials in colon cancer, lung cancer, lymphoma, and growth factor. He has been on the...

8 recent news post(s)
Charles Bennett, M.D., Radiation Oncologist , ROBERT BOISSONEAULT ONCOLOGY INSTITUTECharles Bennett, M.D.

Radiation Oncologist
ROBERT BOISSONEAULT ONCOLOGY INSTITUTE
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Charles Bennett, MD, is a board certified Radiation Oncologist at the Robert Boissoneault Oncology Institute, Florida. He specializes in breast, prostate and metastatic cancer treatment with radiopharmaceauticals. Dr. Bennett has participated in several national forums dealing with radiopharmaceautical...

1 recent news post(s)
Michael Grossbard, MD

Professor of Clinical Medicine
Columbia University College of Physicians and Surgeons
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Michael Grossbard, MD, is a Professor of Clinical Medicine at Columbia University College of Physicians and Surgeons and the Chief of Hematology-Oncology at St. Luke's-Roosevelt Hospital and Beth Israel Medical Center in New York City. His clinical research is in monoclonal antibodies, non-Hodgkin's...

87 recent news post(s)
Brian Abbott, MD, Medical Director of Hematology, Big Sky OncologyBrian Abbott, MD

Medical Director of Hematology
Big Sky Oncology
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Brian Abbott, MD, is the Medical Director of Hematology at Benefis Health System and Sletten Cancer Institute in Great Falls, Montana. He is also Medical Director of the Palliative Medicine program. His specialties include acute and chronic leukemias (AML, ALL, CML, CLL), all forms of lymphomas including...

5 recent news post(s)
Sujith Kalmadi

Staff Physician
Ironwood Cancer & Research Center
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Sujith Kalmadi, MD, is a Staff Physician at the Ironwood Cancer and Research Center in Phoenix, Arizona. Dr. Kalmadi has previously worked as a Clinical Assistant Professor at Baylor school of Medicine in Houston, Texas, and at the Lerner School of Medicine at the Cleveland Clinic, Ohio. He has interest...

View all Leading Experts in this Study Group

GLG NewsSM Analyses by this Study Group's Leading Experts (?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.

Potential impact of large clinical trial on Liquid based cytology market

November 5, 2009

Robert Boorstein, MD, PhD, Associate Professor, Pathology, NEW YORK UNIVERSITY (INC)

Alternative to Pap Test Does Not Appear to Be Better for Detecting Cervical Cancer | www.medcompare.com

The data confirms what has long been known. There has never been definitive evidence for a benefit for Liquid based cytology screening compared with conventional screening, especially when sample collection is standardized and the laboratory meets reasonable standards.Objectively, liquid based cytology...

Triple negative Breast Cancer Strategies

October 14, 2009

Donald Fleming, MD, Division Head of Hematology and Oncology, DAVIS HEALTH SYSTEM INC

MediGene completes patient recruitment into EndoTAGTM-1 phase II breast cancer trial | www.pharmabiz.com

Triple negative Breast cancer has been a phenotype with little hope up until recentlyWhile advances in hormonal therapy and Her2 blocking agents has revolutionized ER/PR + and Her 2 positive breast cancer therapy, triple negative breast cancer pulls down the outcomes, with similar responses as fornon...

Farletuzumab (F) helps the ovarian cancer patients that do well, do well?

September 25, 2009

Donald Fleming, MD, Division Head of Hematology and Oncology, DAVIS HEALTH SYSTEM INC

Farletuzumab Data Presented on Phase II Clinical Trial in First-Relapsed Ovarian Cancer Subjects | www.pipelinereview.com

F recently demonstrated a great majority of platinum sensitive patients respond when given in combination with a platinum based regimen in recurrent ovarian caPlatinum sensitive patients typically do well with platinum based intervention, but it's the platinum resistant ( denovo or delayed) that we...

Herceptin for Her2 + gastric cancer, If you can find one

September 25, 2009

Donald Fleming, MD, Division Head of Hematology and Oncology, DAVIS HEALTH SYSTEM INC

Roche's Herceptin provides impressive survival benefit in HER2-positive advanced gastric cancer | www.pharmabiz.com

Herceptin recently reported in Phase II ASCo data to enhance chemo in Her 2 positive gastric cancer

REGORAFENIB joins a crowd of TKI's for RCC

September 25, 2009

Donald Fleming, MD, Division Head of Hematology and Oncology, DAVIS HEALTH SYSTEM INC

Bayer's anti-cancer drug regorafenib shows stabilization or regression in 81% of kidney cancer patients | www.pharmabiz.com

RCC now has multiple TKI"S either approved or in development for txThe disease control rate seems to be a popular and effective endpoint to get drugs for RCC approved

View All GLG News by members of this Study Group

Members in this Study Group include these company types:

  • Academic Medical Center/Hospital or Clinic
  • Office Based Private Practice or Clinic
  • Non-Academic Community Hospital or Clinic
  • Academic Institution*

Members in this Study Group often have these job titles:

  • Physician - Attending Physician
  • Physician - Division Head
  • Physician - Director
  • Director
  • Partner
  • Professor

Related Study Groups

Study Group Name No. Members
Physicians who Treat Multiple Myeloma (US) 184
Oncologists (US) 2257
Hematologists (US) 998
Oncologists who Treat Hematologic Malignancies (US) 858
Hematologists who Treat Myelodysplastic Syndromes 167
Oncologists Specializing in Hematologic Malignancies in the U.S. 424
Physicians in the U.S. who Treat Patients with Myelodysplastic Syndromes (MDS) 134